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Background: Venous thromboembolism (VTE) is a leading cause of maternal mortality and morbidity, with the highest
incidence occurring during the postpartum period. This study compared the ability of two types of low-molecular-weight
heparin, enoxaparin and bemiparin, to decrease the incidence of VTE following elective caesarean section, emergency
caesarean section, and vaginal delivery in women who had risk factors for thromboembolism.
Methods: In this prospective clinical trial using a sequential group allocation method, 7020 haemodynamically stable
women delivered vaginally or abdominally at the Maternity Teaching Hospital, Kurdistan region, Erbil, Iraq, between
May 1, 2012, and November 1, 2013. These women had risk factors for VTE and were allocated to the following groups:
treatment with 3500 IU/day of bemiparin, 4000 IU/day of enoxaparin, or no intervention (control). The first dose was
administered 6 hours after vaginal or abdominal delivery, or 8 hours after delivery in women receiving spinal
anaesthesia. Subsequent doses were administered daily for up to 6 days. The incidence of VTE was assessed for up
to 40 days postpartum. Data were analyzed using the Statistical Package for Social Sciences version 19. Proportions
were compared using the chi square test of association or Fisher’s exact test. Binary logistic regression analysis was
used with VTE as the dependent variable.
Results: VTE occurred in 1 (0.042%) woman in the bemiparin group, two (0.085%) women in the enoxaparin group,
and nine (0.384%) women in the control group (P = 0.017). Regression analysis showed that women on bemiparin
(OR = 0.106; 95% CI = 0.013–0.838) and enoxaparin (OR = 0.226; 95% CI = 0.049–1.049) were at lower risk of developing
VTE than control women. Adverse events in the enoxaparin group included wound dehiscence, haematoma, and
separation. None of these occurred in the bemiparin group.
Conclusions: Postpartum bemiparin is significantly effective as a prophylaxis for VTE. Wound complications develop
after use of enoxaparin, but not after bemiparin.
Trial registration: ClinicalTrials.gov; Identifier: NCT01588171; date: April 26, 2012.
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Venous thromboembolism (VTE) occurs in frequently.
However, VTE is a leading cause of sickness and death
during pregnancy and puerperium, and its diagnosis and
therapy remain challenging [1]. Approximately 50% of
pregnancy-related pulmonary emboli and more than
30% of pregnancy-related VTEs occur after delivery [2].* Correspondence: shahla_alaf@yahoo.com
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unless otherwise stated.VTE during pregnancy and postpartum remains a major,
but potentially preventable, cause of maternal death and
morbidity. Prevention of VTE mainly involves using an-
ticoagulants for thromboprophylaxis [3].
Evidence available from randomized clinical trials is
inadequate in guiding clinical decision-making on anti-
coagulants during pregnancy and the postpartum period.
Recommendations in guidelines have been based on case
series, extrapolations from non-pregnant patients, and
the opinion of experts [4]. Indeed, a recent systematic
review showed insufficient evidence on which to basehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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methodology and/or small sample sizes for the research
that was available [5]. Recent guidance from the Royal
College of Obstetricians and Gynaecologists (RCOG) and
the National Institute for Health and Clinical Excellence
encourages the use of low-molecular-weight heparin
(LMWH) thromboprophylaxis during pregnancy and after
caesarean and vaginal deliveries for women with risk fac-
tors for VTE [6,7]. The recommendations largely depend
on expert opinion and pay insufficient attention to the po-
tential side effects of thromboprophylaxis. Additionally,
previous studies on VTE did not include women who
were delivered vaginally and almost all of them depended
on caesarean section (CS) as a risk factor.
Among the types of LMWH that are currently used
for VTE prophylaxis, bemiparin, a second-generation
LMWH, and enoxaparin, a first-generation LMWH.
These two LMWHs have different ratios of anti-Xa to
anti-IIa activity (9.7 and 3.9, respectively) [8]. No previ-
ous studies have compared these two different LMWHs
as thromboprophylaxis. The purpose of this trial was to
determine the ability of bemiparin and enoxaparin, rela-
tive to no intervention, to reduce the incidence of post-
partum VTE in women at risk of VTE. This trial also
aimed to compare the incidence of adverse events in the
two interventional groups.
Methods
A prospective clinical trial with the sequential group al-
location method was performed. We included women
aged ≥15 years with risk factors for VTE who delivered
vaginally or by emergency or elective CS at the Maternity
Teaching Hospital, Kurdistan Region, Erbil City, Iraq, be-
tween May 1, 2012, and November 1, 2013.
VTE risk factors after vaginal and abdominal deliveries
were determined based on the RCOG 2009Green-top
Guideline. Women who delivered vaginally were in-
cluded in the study if they had two or more persistent
risk factors for VTE. Women who delivered by elective
CS (category 4) [9] were included if they had one or
more additional risk factors, whereas all women who de-
livered by emergency CS (category 1, 2, or 3) [9] were
included in the study [6]. Other inclusion criteria in-
cluded the absence of active bleeding and haemo-
dynamic stability (pulse <100 beats per min and systolic
blood pressure >100 mmHg). All participants were
deemed capable of providing informed consent. Postpar-
tum haemorrhage (PPH) and severe preeclampsia (PE)
were two risk factors for VTE. LMWH was indicated for
patients with PPH or severe PE after stabilization of the
condition. Women already taking an anticoagulant or
having any contraindication to LMWH, such as ante-
natal or postpartum active bleeding requiring blood
transfusion, placenta previa, thrombocytopenia (plateletcount <75 × 108/μl), severe renal disease (glomerular filtra-
tion rate <30 ml/minute), severe liver disease, or uncon-
trolled hypertension (>200/120 mmHg), were excluded.
Women who were eligible for participation were
assigned to the three arms of the trial: the bemiparin,
enoxaparin, and control groups. Based on a schema pro-
duced by a Microsoft Excel (2007) computer program,
the first woman was recruited to the no-intervention
group (control), the second to the bemiparin group, and
the third to the enoxaparin group, with this sequence re-
peated throughout the trial. This method of recruitment
was necessary owing to the fact that we were unable to
formulate a complete list of all eligible women at one
time and recruit them into the three study groups. This
is because women who were included in the trial had
not been monitored at our centre during pregnancy, and
were seen for the first time during labour.
Data were collected by senior house officers and by
obstetricians on call in the labour room or when prepar-
ing women for elective or emergency CS. These data
collectors were trained by the study investigators regard-
ing risk factors for VTE and consent procedures.
Dehydration in all three groups was avoided by admin-
istering oral and intravenous fluids during labour and
postpartum according to hospital regulations. All women
were encouraged to mobilize during labour and the early
postpartum period. This is because there were no other
types of mechanical methods of thromboprophylaxis
present in the hospital.
Interventional drugs (3500 IU bemiparin or 4000 IU
enoxaparin) were supplied gratis by the hospital, along
with antibiotics, analgesics, and intravenous fluids.
Women were kept in the hospital until they were com-
pletely ambulant. After discharge from the hospital, the
remaining doses of LMWHs were purchased by the
women, together with antibiotics, analgesics, and tonics
that are routinely prescribed to women after delivery. All
in-hospital services (including CS) and drugs were pro-
vided for free during the hospital stay because the Ma-
ternity Teaching Hospital is a public hospital and is
supported by the government. The costs of bemiparin
and enoxaparin were nearly equal and did not constitute
a financial burden after discharge because all of the par-
ticipants were asked regarding their compliance with the
use of injections.
Written consent was obtained by doctors attending
the delivery room who were all trained by the research
team on obtaining informed consent from the partici-
pants. Informed consent was obtained following explan-
ation to and discussion with each participant, and after
answering questions and queries raised by the partici-
pants. Consent was formally documented in the patients’
medical records, and approved by the ethics committee
of the Maternity Teaching Hospital.
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Committee of Hawler Medical University. The same com-
mittee acts as an Institutional Review Board committee in
our institution and approval was gained from both of
them (document No. 1/7, 16/4/2012). The data safety and
monitoring committee of the Maternity Teaching Hospital
consisting of three independent obstetricians from the
hospital ensured continued safety of the patients and on-
going monitoring of adverse events, which were recorded
throughout the trial.
Sample size was estimated using the PS Power and
Sample Size Calculator, Version 3.0. Information en-
tered into the program included an alpha error of 0.01,
a power of 90%, an estimated incidence of VTE among
women who did not receive thromboprophylactic
LMWH of 2 per 1000 [10,11], and an estimated inci-
dence of VTE among women who received enoxaparin
of 1.15% [12]. The estimated sample size was 2209 per
group. To the best of our knowledge, no study has esti-
mated the incidence of VTE in women taking bemi-
parin. Therefore, the estimated sample size was the
same for bemiparin as for enoxaparin. To allow for pa-
tients’ loss to follow-up, each study group consisted of
2340 women.
Women who were recruited to the enoxaparin group
received injections of pre-filled syringes of enoxaparin
sodium 40 mg (Clexane Sanofi-Aventis; equivalent to
4000 IU anti-Xa activity) in 0.4 mL water. Women who
were recruited to the bemiparin group received injec-
tions of 3500 IU bemiparin (Hibor, Laboratories Fcos
ROVI, SA, Madrid, Spain) in 0.2 mL water.
The first dose of bemiparin (3500 IU/) or enoxaparin
(4000 IU) was injected subcutaneously into the upper
aspect of the arm, around the umbilicus, or in the upper
aspect of the thigh 6 hours after vaginal delivery or CS
under general anaesthesia. In women who were adminis-
tered spinal anaesthesia, the first dose was administered
8 hours after delivery. The time of receiving the first
dose was recorded in the files of the patient. The second
dose (3500 IU bemiparin or 4000 IU enoxaparin) was
delivered 24 hours later, and then daily up to a total of
seven doses. Women with severe PE or PPH received
the first dose of LMWH 8–24 hours after delivery.
Stable patients were discharged from the hospital on
the 3rd day after CS when they were completely ambulant
and 24 hours after vaginal delivery. Women were exam-
ined on the 7th day postpartum and 6 weeks after delivery,
and were regarded as free of VTE if there was no sign of
symptomatic VTE 40 days postpartum. Participants con-
firmed regular intake of the interventional drugs when
they were asked about this issue 7 days post-delivery. All
of the women were informed regarding the clinical fea-
tures of VTE. Signs and symptoms of deep vein throm-
bosis (DVT) were defined for the participant as the feelingof pain, swelling, tenderness, discoloration, or redness of
the affected area, and skin that is warm to the touch [13].
Signs and symptoms of PE were defined as the develop-
ment of shortness of breath, rapid heartbeat, sweating and
sharp chest pain [14]. Women were asked to attend the
hospital if they experienced any of these symptoms.
Women presenting with clinical signs or symptoms of
DVT were admitted to the hospital. DVT was confirmed
by compression ultrasound or magnetic resonance im-
aging. Women presenting with signs and symptoms of PE
were referred to the intensive care unit of Erbil Teaching
Hospital. PE was confirmed by computed tomography
pulmonary angiography, and women were admitted to
the unit and remained under observation until they were
stable and discharged home.
The primary outcome measure was the incidence of
symptomatic VTE in the three groups. Secondary out-
come measures included the incidence of side effects and
wound complications in the two intervention groups. Side
effects included bruising or pain at the site of injection,
ecchymosis, allergic skin reactions, itching, urticaria, and
wound haematoma, separation, or dehiscence.
Data were analyzed using the Statistical Package for
Social Sciences (SPSS, version 19). Proportions were
compared using the chi square test of association, or when
applicable, Fisher’s exact test. Binary logistic regression
analysis was used with VTE as the dependent variable.
Variables showing significant association with VTE (by chi
square tests) were entered into a logistic regression model
as independent variables. A P value ≤ 0.05 was considered
statistically significant.
Results
Figure 1 shows the trial profile. Of the 7934 women
interviewed for eligibility, 840 did not meet the inclusion
criteria,36 refused to participate, eight were on an anti-
coagulant during pregnancy, and 30 had contraindica-
tions to heparin (including active bleeding in 11, nine
had thrombocytopenia, and 10 had severe hypertension).
Therefore, 7020 women were recruited and assigned at a
ratio of 1:1:1 to the three study groups (n = 2340 per
group). No women dropped out prior to assessment of
outcome at 40 days in any of the three groups because
the researchers only involved women who were inter-
ested in being followed up for 40 days postpartum and
were on medication as a thromboprophylaxis.
The baseline demographic and clinical characteristics
of the three groups, including the prevalence of risk factors
for VTE, are shown in Table 1.
The primary outcome, symptomatic VTE, was observed
in one (0.043%) woman in the bemiparin group, two
(0.085%) in the enoxaparin group, and nine (0.384%) in
the control group (P = 0.017, Table 2) for the three modes
of delivery. The incidence of symptomatic VTE was 0.5%
Figure 1 Flowchart of the trial.
Table 1 Baseline demographic and clinical characteristics,
including the prevalence of risk factors for VTE
Risk factors for VTE Enoxaparin Bemiparin Control
n = 2340 n = 2340 n = 2340
No. % No. % No. %
-History of APS 0 0 2 0.1 0 0
-Varicose veins 33 1.4 31 1.3 31 1.3
-Heart disease 5 0.2 7 0.3 7 0.3
-Surgery during pregnancy 32 1.4 26 1.1 26 1.1
-Dehydration 10 0.4 18 0.8 2 0.1
-Severe inflammation 15 0.6 16 0.7 0 0
-Pre-eclampsia 147 6.3 123 5.3 125 5.3
-Prolonged labour 173 7.4 148 6.3 174 7.4
-Smoking 42 1.8 31 1.3 36 1.5
-Twin pregnancy 70 3.0 54 2.3 57 2.4
-Postpartum haemorrhage 23 1.0 24 1.0 22 0.9
-Bed rest >3 days 4 0.2 24 1.0 4 0.2
-Wound infection 7 0.3 22 0.9 7 0.3
-Pyelonephritis 8 0.3 37 1.6 28 1.2
-BMI > 30 kg/m2 1222 52.2 1335 57.1 1197 51.2
-Age > 35 years 852 36.4 938 40.1 864 36.9
-Para≥ 4 1201 51.3 1133 48.4 1156 49.4
VTE:venous thromboembolic event; APS: antiphospholipid antibody syndrome;
BMI: body mass index.
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women with a BMI of 25–30 kg/m2, and 0.2% in women
with a BMI >30 kg/m2 (P = 0.003). No other factor was
significantly associated with the incidence of VTE. All
cases of VTE occurred within the first week after delivery.
Women on bemiparin were at lower risk of developing
symptomatic VTE than women in the control group
(odds ratio [OR] =0.106; 95% confidence interval [CI] =
0.013–0.838, Table 3). However, BMI was not significantly
associated with the incidence of VTE.
Table 4 shows that the proportion of women experien-
cing mild side effects (pain and ecchymosis) was signifi-
cantly lower in the bemiparin group than in the enoxaparin
group. Wound dehiscence, hematoma, and separation were
observed in six women in the enoxaparin group, but in no
women in the bemiparin group (P = 0.031).
Six women developed all of the wound complications
together. The wounds were separated in one of the ends
and there was dehiscence in the other end of the wound.
The base of the wounds contained clots and haemato-
mas and there was no sign of infection in the wounds.
Wound complications occurred within the first 3 days
after receiving enoxaparin. Eighteen women in the control
group developed wound infection leading to separation of
the edges at 5–10 days post caesarean section.
The incidence of symptomatic VTE was significantly
lower in the two combined intervention groups (0.64 per
1000 deliveries) than in the control group (3.8 per 1000
Table 2 Relationship between risk factors and the
incidence of VTE
Variables N Venous thromboembolism P
No. %
Interventional groups
Control 2340 9 0.384 0.017*
Bemiparin 2340 1 0.042
Enoxaparin 2340 2 0.085
Age (years)
≤35 4366 8 0.18 1*
>35 2654 4 0.15
BMI (Kg/m2)
<25 586 3 0.5 0.003*
25-29 2680 0 0
30+ 3754 9 0.2
Risk of APS
No 7018 12 0.2 1*
Yes 2 0 0
Varicose veins
No 6925 12 0.2 1*
Yes 95 0 0
Heart Disease
No 7001 12 0.2 1*
Yes 19 0 0
Surgery during pregnancy
No 6936 12 0.2 1*
Yes 84 0 0
Dehydration
No 6990 12 0.2 1*
Yes 30 0 0
Severe inflammation
No 6989 12 0.2 1*
Yes 31 0 0
Pre-eclampsia
No 6625 10 0.2 0.144*
Yes 395 2 0.5
Prolonged labour
No 6525 10 0.15 0.206*
Yes 495 2 0.4
Smoking
No 6911 12 0.17 1*
Yes 109 0 0
Twin pregnancy
No 6839 11 0.16 0.269*
Yes 181 1 0.55
Table 2 Relationship between risk factors and the
incidence of VTE (Continued)
PPH
No 6951 12 0.17 1*
Yes 69 0 0
Bed rest
No 6988 12 0.17 1*
Yes 32 0 0
Wound infection
No 6984 12 0.17 1*
Yes 36 0 0
Pyelonephritis
No 6947 12 0.17 1*
Yes 73 0 0
IVF
*Analysed by Fisher’s exact test.
BMI: body mass index; APS:antiphospholipid antibody syndrome; PPH:
postpartum haemorrhage; IVF: in vitro fertilisation.
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P = 0.004 by Fisher’s exact test).
Thirty women presented with symptoms suspected to
be VTE (in all the 3 groups) all were admitted to the
hospital and assessed accordingly. VTE was not diag-
nosed in these patients, and all were reassured and dis-
charged home. Confirmed cases of DVT were admitted
to the hospital. Therapeutic doses of LMWH were pre-
scribed for them and they were discharged home after
48 hours. These women were advised to use the medica-
tions at home. Women were followed up for 6 weeks
postpartum. Women who were suspected to have PE
were transferred to the intensive care unit at Hawler
Teaching Hospital where facilities were available to con-
firm diagnosis, in addition to treatment and follow-up of
patients.Table 3 Factors significantly associated with VTE by
logistic regression




Bemiparin −2.245 .033 .106 .013 .838
Enoxaparin −1.486 .058 .226 .049 1.049
BMI categories (kg/m2) .615
<25 (Reference) 1
25-29 −15.811 .983 .000 .000
30+ -.660 .324 .517 .139 1.920
Constant −4.525 .000 .011
LMWH: Low-molecular-weight heparin; BMI: body mass index; B: regression
coefficient; OR: odds ratio; CI: confidence interval.




No. (n = 2340) % No. (n = 2340) %
Pain 45 1.9 20 0.85 0.002
Ecchymosis 33 1.4 21 0.89 0.1
Wound dehiscence 6 0.256 0 0 0.031*
Wound separation 6 0.256 0 0 0.031*
Wound Haematoma 6 0.256 0 0 0.031*
(Urticaria, Allergy, Itching) 0 0 0 0 NA
*Analysed by Fisher’s exact test.
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twin pregnancy and underwent emergency CS owing to
fetal distress. She developed severe dyspnea and cyanosis
5 hours after delivery (1 hour before administration of
LMWH). She was in the bemiparin group and died within
10 minutes of resuscitation owing to a major embolus in
the pulmonary system. This patient was excluded from
the analysis.
Discussion
Guidelines of the RCOG and the National Institute for
Health and Clinical Excellence encourage the use of
LMWH as thromboprophylaxis in high-risk pregnancies
and during the postpartum period. However, these rec-
ommendations were largely based on expert opinion
with little evidence from randomized controlled trials
and meta-analyses [3].
We found that the combination of the two groups
who received either enoxaparin or bemiparin resulted in
a postpartum symptomatic VTE rate of 0.64 per 1000
deliveries compared with 3.8 per 1000 in the control
group. Both LMWHs were efficient in decreasing the
rate of VTE, although enoxaparin was more likely than
bemiparin to cause wound complications.
A retrospective cohort study of 653 at-risk gravid
women who received guideline-recommended enoxa-
parin for caesarean thromboprophylaxis showed that 55
(8.5%) of these women experienced wound complica-
tions, including separation and/or hematoma [15]. The
factor Xa-IIa ratio is higher for bemiparin than for enox-
aparin, which may explain the higher rates of hematoma
and other complications in the enoxaparin group [8].
Operative delivery has been reported to place women
at risk for VTE [5,16-18]. Most studies on thrombopro-
phylaxis involved women who delivered via CS [19,20].
A previous study assessed thromboprophylaxis with
unfractionated heparin in 116 parturients with varicose
veins who delivered vaginally or by CS, and showed that
unfractionated heparin significantly reduced the inci-
dence of postpartum venous thrombosis [21]. Notably,
we found that vaginal delivery also entailed a risk of de-
veloping VTE in the absence of thromboprophylaxis. Ofthe780 women in the control group who delivered vagi-
nally, two (0.256%) developed symptomatic VTE com-
pared with no women who delivered vaginally and were
administered bemiparin or enoxaparin. The rate of VTE
in previous studies ranged from 1–3 per 1000 deliveries
[22-25]. We observed a rate of incidence of VTE of 3.8
per 1000 deliveries. The higher rate observed in our
study was likely due to inclusion of women at risk for
VTE, whereas previous studies assessed the rate of post-
partum VTE, irrespective of risk factors or the mode of
delivery.
The major strength of this study was that it was per-
formed in a general public hospital, with over 24,000 de-
liveries per year. This allowed a relatively large sample
size to accrue within a relatively short period of time.
The Maternity Teaching Hospital is the only public hos-
pital in Erbil City and is regarded as a tertiary centre.
One limitation of this study was its open-label design.
We found it difficult to provide the same-shaped pre-
filled syringe containing different materials. The study
was not funded by any drug company, making it difficult
to provide placebo injections. Another limitation was
the absence of lists of women needing thromboprophy-
laxis. Therefore, a pre-prepared method of allocation
concealment could not be formulated for the purpose of
designing the trial as a randomized clinical trial. Add-
itionally, the women had to purchase the two interven-
tional drugs after discharge from the hospital. There
were no regulations and guidelines for postpartum
thromboprophylaxis at the beginning of the research.
However, at the end of this study, most of the obstetri-
cians practicing at the Maternity Teaching Hospital be-
came familiar with the possibility of VTE and its danger
to patients, thus becoming aware of its signs and symp-
toms and modes of prevention. This encouraged the de-
velopment of local guidelines for thromboprophylaxis
and treatment of VTE during pregnancy and the post-
partum period.
Additional research is required to determine the opti-
mal time for administering LMWH. The death of one
woman suggests that administering thromboprophylaxis
earlier than 6 hours may prevent formation of thrombus.
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to mask the interventional drugs from the investigators.
Conclusions
Postpartum bemiparin and enoxaparin are both effective
as prophylaxis for VTE. Wound complications develop
after enoxaparin, but not after bemiparin use.
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